HEM
-
Dr. McNorgan Discusses Hemostemix’s Stem Cell Technology and Potential with Elon Musk’s Neuralink
In this InvestorIntel interview, Tracy Weslosky talks with Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Advisory Board Member Dr.…
-
Thomas Smeenk of Hemostemix talks about market reaction to successful litigation settlement
In this InvestorIntel interview with host Stephen Lautens, Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, President and…
-
Thomas Smeenk on Hemostemix products for Your Fountain of Youth
In a recent InvestorIntel interview, Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV:…
-
Thomas Smeenk with an update on the FDA Phase II clinical trial program of the Hemostemix blood-derived, stem cell therapeutics product (ACP-01)
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV:…
-
Thomas Smeenk on Hemostemix’s autologous stem cell therapy technology and why some call it ‘the fountain of youth’
In a recent InvestorIntel interview, Tracy Weslosky spoke with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…
